Scott+Scott Attorneys at Law LLP Reminds Investors of The Securities Class Action That Has Been Filed Against Iovance Biotherapeutics, Inc. (IOVA)

A securities class action lawsuit has been filed against Iovance Biotherapeutics (IOVA) alleging misleading statements regarding the commercial launch of Amtagvi. The lawsuit, covering the period between May 9, 2024, and May 8, 2025, claims Iovance failed to disclose longer timelines for new Authorized Treatment Centers (ATCs), ineffective patient identification, and higher patient drop-offs, leading to increased costs and lower revenue. The suit was triggered by Iovance's May 8, 2025, announcement of Q1 2025 revenue of $49.3 million, down from $73.7 million the prior quarter, and a slashed FY25 revenue guidance from $450-$475 million to $250-$300 million, causing IOVA shares to decline 44.8% to $1.75.

Analysis

Iovance Biotherapeutics (NASDAQ: IOVA) is confronted with a securities class action lawsuit alleging that the company and its leadership issued false and/or misleading statements and failed to disclose material adverse facts regarding the commercial launch of its key product, Amtagvi, a cell therapy for metastatic melanoma. The class period spans from May 9, 2024, to May 8, 2025. The core allegations point to significant operational headwinds, including protracted timelines for new Authorized Treatment Centers (ATCs) to begin administering Amtagvi, inefficiencies within the sales team and new ATCs in patient identification and selection resulting in higher patient attrition, and a consequent mismatch between manufactured product and ATC capacity, leading to elevated costs and diminished revenue. These issues came to light on May 8, 2025, when Iovance reported Q1 2025 total product revenue of $49.3 million, a substantial decrease from the $73.7 million recorded in the preceding quarter. Simultaneously, the company dramatically revised its FY25 total product revenue guidance downwards, from an initial $450-$475 million to $250-$300 million, citing "recent launch dynamics" and challenges with ATC growth and treatment timelines. The market's reaction was severe, with Iovance's stock price plummeting by 44.8% to $1.75 per share on May 9, 2025, on unusually heavy trading volume, reflecting a strongly negative sentiment (ticker sentiment: -0.9) towards the company's disclosures and revised outlook.

Key Decisions for Investors

• Investors should exercise extreme caution given the significant operational challenges revealed in Amtagvi's commercialization, the drastic reduction in FY25 revenue guidance, and the overhang of the securities class action lawsuit.
• Existing shareholders in Iovance Biotherapeutics may need to re-evaluate their investment thesis, considering the 44.8% share price decline and the newly disclosed risks impacting the company's primary revenue driver.
• Potential investors should closely monitor Iovance's ability to rectify the issues with Authorized Treatment Center ramp-up, patient identification, and overall commercial execution before considering an entry point, alongside developments in the ongoing litigation.